Spinal Muscular Atrophy Market

Market Overview:

The 7 major spinal muscular atrophy markets reached a value of US$ 3.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 13.0 Billion by 2034, exhibiting a growth rate (CAGR) of 14.28% during 2024-2034.

The spinal muscular atrophy market has been comprehensively analyzed in IMARC's new report titled "Spinal Muscular Atrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Spinal muscular atrophy (SMA) is a rare genetic ailment that affects the motor neurons in the spinal cord, leading to progressive muscle weakness and atrophy. It is classified into four different types based on the age of onset and severity of symptoms: types 1, 2, 3, and 4. Some of the common symptoms of spinal muscular atrophy are difficulty with movement, weakness in the limbs, poor muscle tone, delayed motor milestones, joint contractures, etc. Other indications of SMA may include tremors, scoliosis, respiratory problems, and difficulty with swallowing or speaking. The diagnosis of spinal muscular atrophy (SMA) typically involves a combination of clinical evaluation, genetic testing, and imaging studies. In addition to conducting blood tests to check for genetic abnormalities linked to SMA, doctors may perform a physical examination to evaluate muscular strength, tone, and reflexes. Numerous imaging studies, such as magnetic resonance imaging (MRI) or electromyography (EMG), are also used to examine the muscles and nerves. Genetic testing can confirm the presence of SMN1 mutations, identify carriers of the disease, and help determine the type and severity of SMA.

The rising prevalence of rare genetic diseases and the escalating need for developing novel treatment regimens for such ailments are primarily driving the spinal muscular atrophy market. In addition to this, the widespread adoption of medications, including nusinersen and risdiplam, which increase the production of the SMN protein and improve motor function and survival in patients with SMA is also bolstering the market growth. Moreover, the implementation of newborn screening for SMA, which involves testing newborns for the presence of the SMN1 gene, is further propelling the market. Early detection through newborn screening can enable effective treatment and possibly better outcomes for affected children. Besides this, several key players are making extensive investments in research activities for the development of disease-modifying therapies that target the underlying cause of SMA. This, in turn, is acting as another significant growth-inducing factor. Additionally, the increasing utilization of respiratory support, such as non-invasive ventilation and cough assist devices, to help individuals with SMA manage respiratory complications is also creating a positive outlook for the market. Apart from this, the emerging popularity of gene therapy, which improves survival, motor function, and quality of life in patients with SMA type 1, is expected to drive the spinal muscular atrophy market in the coming years.

IMARC Group’s new report provides an exhaustive analysis of the spinal muscular atrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for spinal muscular atrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the spinal muscular atrophy market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the spinal muscular atrophy market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the spinal muscular atrophy market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current spinal muscular atrophy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the spinal muscular atrophy market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the spinal muscular atrophy market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the spinal muscular atrophy market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of spinal muscular atrophy across the seven major markets?
• What is the number of prevalent cases (2018-2034) of spinal muscular atrophy by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of spinal muscular atrophy by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of spinal muscular atrophy by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with spinal muscular atrophy across the seven major markets?
• What is the size of the spinal muscular atrophy patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of spinal muscular atrophy?
• What will be the growth rate of patients across the seven major markets?
   

Spinal Muscular Atrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for spinal muscular atrophy drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the spinal muscular atrophy market?
• What are the key regulatory events related to the spinal muscular atrophy market?
• What is the structure of clinical trial landscape by status related to the spinal muscular atrophy market?
• What is the structure of clinical trial landscape by phase related to the spinal muscular atrophy market?
• What is the structure of clinical trial landscape by route of administration related to the spinal muscular atrophy market?